← Back to Search

TMS for Approach/Avoidance Conflict

N/A

Recruiting

Led By Alexander Opitz, PhD

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age between 18 and 65 years old.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediate effect during stimulation

Awards & highlights

Study Summary

This trial is testing whether TMS can change the way people approach or avoid things by manipulating the theta oscillations in the prefrontal cortex.

Who is the study for?

This trial is for English-speaking adults aged 18-65 without drug or alcohol addiction, no metal/electric implants in head/neck/chest, not on long-term medications, and not pregnant/breastfeeding. Those with a history of seizures, significant head injuries, or chronic neurological/mental disorders cannot join.Check my eligibility

What is being tested?

The study tests if stimulating the brain with TMS at specific times during its theta wave cycle can affect decision-making related to approach or avoidance behavior. It's examining the direct influence of brain activity patterns on this type of behavior.See study design

What are the potential side effects?

TMS may cause discomfort at the stimulation site, headache, lightheadedness, or tingling. Rarely it could induce seizures or temporary hearing changes due to the noise during application.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 65 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediate effect during stimulation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediate effect during stimulation

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediate effect during stimulation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reaction times in the Approach/Avoidance test

Secondary outcome measures

Amplitude of TMS evoked potentials

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: TMS over the left prefrontal cortexExperimental Treatment1 Intervention

Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the left dorsolateral prefrontal cortex (DLPFC) at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing and stimulation per session is approximately 40 minutes (in 4 blocks with breaks in-between).

Group II: TMS over the head vertexPlacebo Group1 Intervention

Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the head vertex at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing per session is approximately 40 minutes (in 4 blocks with breaks in-between).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Transcranial magnetic stimulation (TMS)

2013

Completed Phase 4

~510

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH

2,784 Previous Clinical Trials

2,689,249 Total Patients Enrolled

University of MinnesotaLead Sponsor

1,379 Previous Clinical Trials

1,588,470 Total Patients Enrolled

Alexander Opitz, PhDPrincipal InvestigatorUniversity of Minnesota

3 Previous Clinical Trials

128 Total Patients Enrolled

Media Library

Transcranial magnetic stimulation (TMS) Clinical Trial Eligibility Overview. Trial Name: NCT05416138 — N/A

Approach/Avoidance Conflict Research Study Groups: TMS over the left prefrontal cortex, TMS over the head vertex

Approach/Avoidance Conflict Clinical Trial 2023: Transcranial magnetic stimulation (TMS) Highlights & Side Effects. Trial Name: NCT05416138 — N/A

Transcranial magnetic stimulation (TMS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05416138 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who qualifies for participation in this clinical research study?

"Aspirants to this experimental trial must present with approach/avoidance behavior and be within the 18-65 age range in order to qualify. In total, 26 individuals will be inducted into the study."

Answered by AI

What is the aggregate number of participants engaging in this clinical trial?

"Affirmative. The data available on clinicaltrials.gov demonstrates that this research endeavour, which was first posted on September 11th 2022, is actively recruiting volunteers. In total, 26 patients need to be signed up from a single medical facility."

Answered by AI

Is the age threshold for participants in this research extending beyond octogenarians?

"This research trial is searching for volunteers that are of legal age and under 65 years old."

Answered by AI

Is enrollment for this research currently open to participants?

"Correct. Clinicaltrials.gov states that this medical experiment, which was first announced on September 11th 2022, is currently seeking participants. Twenty six patients must be recruited from a single site to complete the trial's enrollment goals."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Theta Phase-specific TMS to Modulate Prefrontal Activity

2022. "Theta Phase-specific TMS to Modulate Prefrontal Activity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05416138.